High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.

Abstract

The interleukin-6 family cytokine, oncostatin-M (OSM) has been associated with response to tumor necrosis factor-α antagonists (anti-TNFs) in small cohorts of patients with inflammatory bowel disease (IBD). We aimed to evaluate the association between plasma OSM concentrations and response to anti-TNFs (infliximab and adalimumab) in both ulcerative colitis (UC) and Crohn's disease (CD). A retrospective cohort study was conducted in patients with IBD with a history of anti-TNF exposure. Blood samples, collected prior to anti-TNF exposure, were analyzed by enzyme-linked immunosorbent assay for the presence and quantity of OSM. Clinical remission was assessed at 1-year post anti-TNF exposure in addition to the occurrence of surgery, hospitalization, corticosteroid use, and adverse drug events. Lastly the threshold OSM plasma concentration associated with anti-TNF non-response was assessed by receiver operator characteristic (ROC) curve analysis. Patients with IBD (CD, n = 82; UC, n = 40) were assessed. In both UC and CD, mean pre-treatment OSM concentrations were significantly lower in those who achieved clinical remission at 1-year (p < 0.0001). A threshold plasma OSM concentration of 168.7 pg/ml and 233.6 pg/ml respectively separated those who achieved clinical remission at 1-year on an anti-TNF from those who did not in CD and UC respectively (CD: area under the receiver operator characteristic curve, AUROC = 0.880, 95% CI 0.79-0.96; UC: AUROC = 0.938, 95% CI 0.87-1.00). High OSM concentrations were associated with anti-TNF discontinuation and use of rescue steroids in CD and UC. High pre-treatment OSM concentrations identify IBD patients at-risk of anti-TNF non-response at 1-year as well as other deleterious clinical outcomes.

• Authors: Angela Guo, Cameron Ross, Nilesh Chande, Jamie Gregor, Terry Ponich, Reena Khanna, Michael Sey, Melanie Beaton, Brian Yan, Richard B Kim, Aze Wilson
• Journal: Scientific reports (Sci Rep) Vol. 12 Issue 1 Pg. 1185 (01 24 2022) ISSN: 2045-2322 [Electronic] England
• PMID: 35075155 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Biomarkers
• Tumor Necrosis Factor Inhibitors
• Oncostatin M

Topics

• Adolescent
• Adult
• Aged
• Biomarkers (blood)
• Female
• Humans
• Inflammatory Bowel Diseases (blood, drug therapy)
• Male
• Middle Aged
• Oncostatin M (blood)
• Retrospective Studies
• Tumor Necrosis Factor Inhibitors (therapeutic use)
• Young Adult